EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment

Ezio Zanon iD

Diagnostics · 23.01.2023 · 13 (3) · 420

DOI: 10.3390/diagnostics13030420 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 23.01.2023. Verfasst von Ezio Zanon. Beteiligte Einrichtung: Department of Medicine Via Giustiniani, Haemophilia Centre, University Hospital of Padua, 35128 Padua, Italy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired haemophilia A (AHA) is a rare bleeding disorder caused by inhibitory autoantibodies against coagulation factor VIII (FVIII). AHA is a disease that most commonly affects the elderly but has also been observed in children and in the postpartum period. AHA is idiopathic in 50% of cases and is associated with autoimmune diseases, malignancies, and infections in the remaining 50%. Recently, cases of association between AHA, COVID-19 vaccination, and infection have been reported in the literature. For diagnoses, determining FVIII levels is crucial to distinguish the different causes of aPTT prolongation. Treatment of AHA is based on bypassing agents (recombinant factor VIIa, activated prothrombin complex concentrate) and porcine FVIII to control the bleeding and immunosuppressive therapy (corticosteroids, rituximab, cyclophosphamide) to suppress autoantibody production. It is important to start a prophylactic regimen to prevent further bleeding episodes until the inhibitor is negative. Recently, the series of cases reported in the literature suggest that emicizumab may provide effective and safe haemorrhage prophylaxis in the outpatient setting.

Schlagwörter

Stichwörter der Autor:innen

COVID-19acquired hemophilia Abypassing agentsemicizumab

Autor:innen und Institutionen

  • Department of Medicine Via Giustiniani, Haemophilia Centre, University Hospital of Padua, 35128 Padua, Italy.

ORCID-Profile: Ezio Zanon

Zitieren

APA

Zanon, E. (2023). Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment. Diagnostics, 13(3), 420. https://doi.org/10.3390/diagnostics13030420

Vancouver

Zanon E. Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment. Diagnostics. 2023;13(3):420. doi:10.3390/diagnostics13030420

BibTeX
@article{Zanon2023,
  author = {Zanon, Ezio},
  title = {Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment},
  journal = {Diagnostics},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {420},
  doi = {10.3390/diagnostics13030420}
}
Kostenlos starten →